@article{ref1,
title="Platelet serotonin transporter in depressed children and adolescents: 3H-paroxetine platelet binding before and after sertraline",
journal="Journal of the American Academy of Child and Adolescent Psychiatry",
year="1998",
author="Sallee, F. R. and Hilal, R. and Dougherty, D. and Beach, K. and Nesbitt, L.",
volume="37",
number="7",
pages="777-784",
abstract="OBJECTIVE: To evaluate serotonin transporter protein (5HTPR) binding in platelets from children and adolescents with major depression (MDD) compared to normal controls using the selective ligand 3H-paroxetine. METHOD: Children and adolescents with MDD (n = 24) defined by DSM-III-R criteria and normal controls (n = 22) were compared by platelet 5HTPR kinetic analysis with the hypothesis that 5HTPR is reduced in MDD. A subset of MDD subjects (n = 18) continued to participate in a fixed-dose, open-label sertraline trial for 6 weeks followed by drug-free washout and repeated 5HTPR analysis. RESULTS: Sex, prepubertal status, and age had no effect on 5HTPR. Medication-free MDD subjects differed from controls in reduced binding capacity (Bmax) (p < .001). Sertraline therapy decreased binding affinity from baseline non-selectively (p < .05), and Bmax elevation from baseline was associated with nonresponse and suicide attempt history. CONCLUSION: Earlier literature in this population is replicated with regard to reduced platelet 5HTPR Bmax in MDD. Findings support a continuum of 5HTPR involvement in MDD across the developmental spectrum.<p /><p>Language: en</p>",
language="en",
issn="0890-8567",
doi="10.1097/00004583-199807000-00018",
url="http://dx.doi.org/10.1097/00004583-199807000-00018"
}